In this context, the main strategies to boost NK-cell function against CRC could rely on the use of mAbs or BiKEs targeting CRC tumor antigens (e.g., EGFR, CEA, HER2, MUC-1 and LGR5) that can directly induce tumor cell death but also simultaneously trigger NK cell cytotoxicity via ADCC (39). The gene discussed is LGR5; the disease is neoplasm.